title: Cellular effects of leishmanial tubulin inhibitors on L. donovani.
abstract: To aid our investigation of tubulin as an antileishmanial drug target, the effects of the mammalian antimicrotubule agents ansamitocin P3, taxol, and hemiasterlin on Leishmania donovani promastigotes were described. These drugs affected the assembly of purified leishmanial tubulin and inhibited the growth of L. donovani promastigotes at micromolar concentrations. When promastigotes were treated with these agents, mitotic partitioning of nuclear DNA and cytokinesis were usually inhibited. The spatial orientation of kinetoplasts was often disturbed, suggesting a role for microtubules in the segregation of these organelles during mitosis. Aberrant cell types produced in drug-treated cultures included parasites with one nucleus and two geometrically distinct kinetoplasts, parasites with multiple kinetoplasts, and cytoplasts containing a kinetoplast but no nucleus. A subset of unique cell types, parasites containing two nuclei, a spindle fiber, and two geometrically distinct kinetoplasts, were observed in hemiasterlin-treated cultures. Flow cytometric analysis of L. donovani promastigotes treated with these three drugs indicated a dramatic shift toward the G2 + M phase of the cell cycle, with some cells containing four times the amount of DNA present in G1. These results were used to evaluate the cellular effects of WR85915, an aromatic thiocyanate with in vitro antileishmanial and anti-tubulin activity, on L. donovani. Treatment of parasites with WR85915 did not produce the unusual cell types described above and did not cause the accumulation of parasites in G2 + M, suggesting that WR85915 acts on target(s) in Leishmania in addition to tubulin. These studies validate tubulin as a suitable antileishmanial drug target and provide criteria to assess the cellular mechanism of action of new candidate antileishmanial agents.
authors.affiliation: Department of Parasitology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.
authors.forename: C G
authors.initials: CG
authors.lastname: Havens
authors.forename: N
authors.initials: N
authors.lastname: Bryant
authors.forename: L
authors.initials: L
authors.lastname: Asher
authors.forename: L
authors.initials: L
authors.lastname: Lamoreaux
authors.forename: S
authors.initials: S
authors.lastname: Perfetto
authors.forename: J J
authors.initials: JJ
authors.lastname: Brendle
authors.forename: K A
authors.initials: KA
authors.lastname: Werbovetz
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D016054:DNA, Protozoan / Q000032:analysis; D005434:Flow Cytometry; D007893:Leishmania donovani / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D008453:Maytansine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D009842:Oligopeptides / Q000494:pharmacology*; D010069:Oxadiazoles / Q000494:pharmacology*; D017239:Paclitaxel / Q000494:pharmacology*; D014404:Tubulin / Q000378:metabolism*
chemical_list: D000981:Antiprotozoal Agents; D016054:DNA, Protozoan; D009842:Oligopeptides; D010069:Oxadiazoles; D014404:Tubulin; C425293:WR 85915; C103465:hemiasterlin A; D008453:Maytansine; C015682:ansamitocins; D017239:Paclitaxel